Myelodysplastic Syndromes

<p>Written by a team of leading authorities in pathogenesis diagnostic techniques and clinical management strategies in myelodysplastic syndrome (MDS) this text provides a concise easy-to-follow review of the advances in the science classification diagnosis and management of the condition. </p><p>An ideal source for hematologists oncologists and cancer researchers this <strong><em>Second Edition</em></strong> features:</p><ul> <li>a new eight-page color insert</li> <li>200 color and black-and-white illustrations</li> <li>reworked content organized into three sections: MDS epidemiology and biology; diagnosis classification and prognosis; and MDS therapy</li> <li>thoroughly updated chapters reflecting a shift from the topical focus as dictated by the evolution of the field</li> </ul><p>New topics in <strong><em>Myelodysplastic Syndrome </em></strong>include:</p><ul> <li>del(5q) and 5q-syndrome CMML and MDS-MPD overlap syndrome</li> <li>the reborn DNA methyltransferase inhibiting nucleoside analogs</li> <li>the diagnosis of chronic myelomonocytic leukemia and other MDS cases with myeloproliferative features</li> <li>the role of mitochondria and the potential importance of iron overload in MDS</li> <li>global genomics approaches such as cDNA expression arrays array-based comparative genomic hybridization and single nucleotide polymorphism array</li> <li>the role of abnormal mitochondrial ferritin accumulation and other mitochondrial metabolic anomalies in MD</li> <li>other disease-associated alterations such as abnormalities of B lymphocyte populations in MD</li> <li>three recently approved drugs: azacitidine lenalidomide and decitabine</li> </ul>